Maximize Your PGx Reimbursements

Pharmacogenomics (PGX) lab testing is expected to hit $12B by 2026. Learn how Labs can navigate the PGx reimbursement landscape and capitalize on market growth opportunities.

Dec 8, 2022 at 11:00 am PT
  • Evolving PGx reimbursement policies and trends
  • Factors driving PGx reimbursement
  • Maximize PGx reimbursements via accurate, clean data

Register Now

About the Speakers

Paul Sanders

Vice President and Head of the Lab Business Unit, 1health

Paul Sanders is the Vice President and Head of the Lab Business Unit at, an industry-leading software and services company that helps diagnostic laboratories to expand revenue. Prior to 1health, Mr. Sanders served in multiple leadership positions at Abbott Vascular, Boston Scientific and Medtronic, directing more than 20+ new product launches, including several billion dollar global brands. He also served as Vice President at LipoScience and as President for Marketing and Clinical Product Strategy for a molecular hereditary cancer diagnostics company.

Trusted Partners